Savara INC 8-K filings

Savara Inc. announced the approval of significant amendments to its Certificate of Incorporation and 2024 Omnibus Incentive Plan, alongside executive transitions, during its annual stockholder meeting.

Savara Inc. has entered into a new lease agreement for approximately 10,795 square feet of office space in Yardley, PA, to serve as its new headquarters, commencing July 1, 2026.

Savara Inc. amended its loan agreement with Hercules Capital, Inc., restructuring access to $75 million in additional term loans contingent on FDA approval of MOLBREEVI and extending financial covenant compliance dates.

Savara Inc. updated its corporate presentation, detailing positive Phase 3 results for MOLBREEVI in autoimmune PAP and outlining its commercialization strategy.

Savara Inc. announced the pricing of a $130.0 million public offering of common stock and pre-funded warrants to fund clinical development and commercialization activities.

Savara Inc. announced a $75 million non-dilutive royalty funding agreement with RTW Investments, LP to support the potential U.S. launch of its investigational drug MOLBREEVI for autoimmune PAP, contingent on FDA approval.

Savara Inc. updated its corporate presentation, showcasing positive Phase 3 IMPALA-2 trial results for MOLBREEVI in autoimmune PAP and an expanded U.S. market opportunity.

Savara Inc. announced the results of its Annual Meeting of Stockholders held on June 5, 2025, where all director nominees were elected, the independent auditor was ratified, and executive compensation was approved on an advisory basis.

Savara Inc. announced it received a Refusal to File letter from the FDA for its Biologics License Application for MOLBREEVI, citing incomplete Chemistry, Manufacturing, and Controls data, delaying potential approval until a Q4 2025 resubmission.

Savara Inc. has terminated its $100 million at-the-market (ATM) offering agreement with Evercore Group L.L.C., effective April 2, 2025.

Savara Inc. has entered into a loan agreement with Hercules Capital for up to $200 million to support the development and potential commercialization of MOLBREEVI for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc. has set target bonus amounts for its executive officers for the year ending December 31, 2025, based on a mix of corporate and individual performance measures.

Savara Inc. has released an updated corporate presentation highlighting positive Phase 3 trial results for MOLBREEVI in treating autoimmune Pulmonary Alveolar Proteinosis (aPAP) and outlining commercialization plans.

Savara Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $100 million underwritten offering of its common stock.

Savara Inc. announced positive topline results from its Phase 3 IMPALA-2 clinical trial, demonstrating the efficacy and safety of molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc. has amended its previous 8-K filing to include the full details of the newly approved 2024 Omnibus Incentive Plan.

Savara Inc. stockholders approved an amendment to the company's charter to allow for officer exculpation and elected directors at the annual meeting on June 6, 2024.

Savara Inc. reports that a director will not seek reelection and Bain Capital Life Sciences has waived its right to designate a board member.

Savara Inc. has signed a Master Services Agreement with Fujifilm to continue development and manufacturing of the active pharmaceutical ingredient for its molgramostim product candidate.

Savara Inc. has set target bonus amounts for its executive officers for the year ending December 31, 2024, with payouts tied to corporate and individual performance.